NSEIssue of Securities1d ago · 30 Oct 2026, 03:18 pm
Issue of Securities
Sudarshan Pharma Industries Limited · SUDARSHAN
✦ AI SummaryFundraise
Sudarshan Pharma Industries Limited has informed the Exchange about issue of Securities, specifically the proposal to raise funds through the issue and allotment of up to 72,00,00,000 warrants convertible into equity shares at a price to be determined, subject to regulatory approvals and shareholder approval at an EGM.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk3/10
Liquidity Impact7/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sudarshan Pharma Industries Limited has informed the Exchange about issue of Securities
Attachments (1)
📄pdf
Download →
SUDARSHAN_30102026151743_Sudarshan_Outcome_Warrants_BM_30_10_2026.pdf
View document text
EUDAREHAI PHAR]IA IIIDUOTRIET TTD
Head Otlice : 301. Aura Biplex, Premium Retail Premises, 7, S.V Boad Borival (West), Nlurnba '400092
E-mail : comp iance@sudarshanpharma.com Website : www.sudarshanpharma.com
BoardLine: i91 22-42221111 i43331111 i42221116 (100 line) . CIN : 151496[,1H200BPLC1 84997
sP L/ CS/SE/ 2A26-2O2t /12 Date: 3olh October 2026
The Ljsting Department The [isting Department
BSE Limited National Stock Exchange of lndia Limited,
Phlroze.leejeebhoy Towers, Exchange Plaza, C 1, Block G,
Da alStreet, Bandra Kurla Complex, Bandra (E),
Mumbai 400 001 Mumbai- 400 051
BSE Scrip Code: 543828 NSE Trading Symbol: SUDARSHAN
Ref: Regulation 30 ofSEB| (Listing Obligations And Disclosure Requirements) Regulations, 2015
Sub: Out.ome of the Meeting of Board of Dire.tors of the Company held on Thursday,
29rh October, 2026
Dea r Sir / Madam,
This s to lnform you that the Board of Directors of the Company at its Board meeting held on
291' October, 2026 has approved the proposa to raising of fLrnds through issue and alotment of up
to 72,00,00,000 (Sevefty Two Crores) Warrafts, each Warrant coovertible into 1(one) Equity Share
of thef-a.eVaueof Re.1/ (RupeeOneOnly) ntermsofChapterVoftheSEBl (tssue of Capital and
Dsclosure Requlrements) Regulations, 2018, as amended ("5EBl ICDR Regulations") on a
preferent a basisto N/lr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company at a price
to be determined as per Regulation 164 of the SEBt |CDR Regulations, subject to the approval of
regu atory / statutory authorities and the members of the Company at an Extraordinary General
[/]eetlng ("EGM").
The Board wi I be seeklng shareholders' approval in an EGM, Notice of whlch will be issued
separately.
The meeting of the Board of Directors commenced at 7.00 pm and concluded at 10.00 pm
We request you to klndly take the above informatlon on record
Thanl(s & Regards,
You rs faithfully,
For Sudarshan Pharma lndustries
Sach n Mehta ,9
Joint Managing Director
Regd. Off. : 301, Aura Biplex, Above Kalyan Jewellers, S.V Road, Borivali (West), [,4umbai -400092